VivoSim Labs announced that its AI-enabled 3D human tissue models, NAMkind™ Liver and GI, demonstrated over 90% sensitivity in predicting liver toxicity, significantly outperforming traditional animal testing methods which have 50-65% sensitivity. These models also reduce false positives to under 5%, helping pharmaceutical companies avoid costly drug development errors. The technology is gaining traction as the FDA encourages a shift from animal testing to human-relevant methods. VivoSim's models also accurately predict toxicity for advanced therapies like Antibody Drug Conjugates (ADCs), supporting safer drug development. The data was presented at the European Society of Toxicology conference in 2026.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
